Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Diagnostic evaluation of women with suspected breast cancer

Laura J Esserman, MD, MBA
Bonnie N Joe, MD, PhD
Section Editors
Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
Daniel F Hayes, MD
Deputy Editor
Wenliang Chen, MD, PhD


Approximately 230,480 American women are diagnosed with breast cancer annually, and 39,520 women die from this disease [1]. Global cancer statistics show that breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23 percent of total cancer cases and 14 percent of cancer deaths [2]. Breast cancer is now also the leading cause of cancer death among females in economically developing countries.

Despite increasing incidence rates, annual mortality rates from breast cancer have decreased over the last decade (1.9 percent per year from 2008 to 2012) [3]. The decline has been more pronounced in Caucasian than in African-American women. (See "Factors that modify breast cancer risk in women".)

A significant portion of the decline in mortality is attributable to the impact of screening mammography, which permits diagnosis at an earlier stage of disease [4-7]. Preinvasive breast cancer (ductal carcinoma in situ [DCIS]) now accounts for 25 to 30 percent of all newly diagnosed, mammographically detected breast cancers. (See "Screening for breast cancer: Strategies and recommendations" and "Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis", section on 'Mammographic screening'.)

The majority of breast cancers are diagnosed as a result of an abnormal mammogram, but not all mammographic findings represent cancer. Women who have an abnormal screening mammogram often need further diagnostic evaluation with additional mammographic views such as spot-compression magnification views or spot tomosynthesis views and/or targeted ultrasonography to determine the need for tissue sampling or biopsy. Additionally, not all cancers are detectable on mammography. A clinically suspicious mass should also be biopsied, regardless of imaging findings, as approximately 15 percent of such lesions can be mammographically occult [8]. The goal of the initial biopsy is to obtain sufficient diagnostic material using the least invasive approach and to avoid surgical excision of benign lesions. (See "Breast biopsy".)

This review will discuss the diagnostic evaluation and management of a woman with suspected breast cancer due to either abnormal imaging or physical findings. Initial staging workup of patients with newly diagnosed breast cancer, the general approach to evaluation of breast masses in women, and breast biopsy techniques are discussed separately. (See "Clinical features, diagnosis, and staging of newly diagnosed breast cancer" and "Clinical manifestations and diagnosis of a palpable breast mass" and "Breast biopsy".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jul 13, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.
  2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.
  3. Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst 2015; 107:djv048.
  4. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784.
  5. de Gelder R, Heijnsdijk EA, Fracheboud J, et al. The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy. Int J Cancer 2015; 137:165.
  6. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer 2011; 117:714.
  7. Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst 2014; 106.
  8. Barlow WE, Lehman CD, Zheng Y, et al. Performance of diagnostic mammography for women with signs or symptoms of breast cancer. J Natl Cancer Inst 2002; 94:1151.
  9. Chang JH, Vines E, Bertsch H, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 2001; 91:1231.
  10. Smart CR, Hartmann WH, Beahrs OH, Garfinkel L. Insights into breast cancer screening of younger women. Evidence from the 14-year follow-up of the Breast Cancer Detection Demonstration Project. Cancer 1993; 72:1449.
  11. Stomper PC, Winston PS, Proulx GM, et al. Mammographic detection and staging of ductal carcinoma in situ: mammographic-pathologic correlation. Semin Breast Dis 2000; 3:1.
  12. Lin C, Moore D, DeMichele A, et al. Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening (abstract 1503). (Abstract available online at www.abstract.asco.org/AbstView_65_31279.html, accessed February 11, 2010). J Clin Oncol 2009; 27:1503s.
  13. Sprague BL, Arao RF, Miglioretti DL, et al. National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology 2017; 283:59.
  14. Lehman CD, Arao RF, Sprague BL, et al. National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology 2017; 283:49.
  15. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System, 5th ed, D’Orsi CJ, Sickles EA, Mendelson EB, et al (Eds), American College of Radiology, Reston, VA 2013.
  16. Stomper PC. Breast imaging. In: Atlas of Breast Cancer, Hayes DF (Ed), Mosby, Philadelphia 2000. p.54.
  17. Harvey JA, Nicholson BT, Lorusso AP, et al. Short-term follow-up of palpable breast lesions with benign imaging features: evaluation of 375 lesions in 320 women. AJR Am J Roentgenol 2009; 193:1723.
  18. Stomper PC, Geradts J, Edge SB, Levine EG. Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. AJR Am J Roentgenol 2003; 181:1679.
  19. Venkatesan A, Chu P, Kerlikowske K, et al. Positive predictive value of specific mammographic findings according to reader and patient variables. Radiology 2009; 250:648.
  20. Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014; 15:e234.
  21. Sickles, EA, D’Orsi CJ, et al. ACR BI-RADS Mammography. In: ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System, 5th ed, D’Orsi CJ, Sickles EA, Mendelson EB, et al (Eds), American College of Radiology, Reston, VA 2013.
  22. Holland R, Hendriks JH, Vebeek AL, et al. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990; 335:519.
  23. Kopans DB, Lindfors K, McCarthy KA, Meyer JE. Spring hookwire breast lesion localizer: use with rigid-compression mammographic systems. Radiology 1985; 157:537.
  24. Healey EA, Osteen RT, Schnitt SJ, et al. Can the clinical and mammographic findings at presentation predict the presence of an extensive intraductal component in early stage breast cancer? Int J Radiat Oncol Biol Phys 1989; 17:1217.
  25. Gluck BS, Dershaw DD, Liberman L, Deutch BM. Microcalcifications on postoperative mammograms as an indicator of adequacy of tumor excision. Radiology 1993; 188:469.
  26. Waddell BE, Stomper PC, DeFazio JL, et al. Postexcision mammography is indicated after resection of ductal carcinoma-in-situ of the breast. Ann Surg Oncol 2000; 7:665.
  27. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).
  28. Baines CJ, Dayan R. A tangled web: factors likely to affect the efficacy of screening mammography. J Natl Cancer Inst 1999; 91:833.
  29. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92:1081.
  30. Fish EB, Chapman JA, Link MA. Assessment of tumor size for multifocal primary breast cancer. Ann Surg Oncol 1998; 5:442.
  31. Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol 2005; 23:7497.
  32. Andea AA, Wallis T, Newman LA, et al. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 2002; 94:1383.
  33. Morris EA, Schwartz LH, Drotman MB, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000; 214:67.
  34. Shen J, Hunt KK, Mirza NQ, et al. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 2004; 101:1330.
  35. Egan RL, McSweeney MB. Intramammary lymph nodes. Cancer 1983; 51:1838.
  36. Jadusingh IH. Intramammary lymph nodes. J Clin Pathol 1992; 45:1023.
  37. Stomper PC, Leibowich S, Meyer JE. The prevalence and distribution of well circumscribed nodules on screening mammography: Analysis of 1500 mammograms. Breast Dis 1991; 4:197.
  38. Upponi S, Kalra S, Poultsidis A, et al. The significance of intramammary nodes in primary breast cancer. Eur J Surg Oncol 2001; 27:707.
  39. Günhan-Bilgen I, Memiş A, Ustün EE. Metastatic intramammary lymph nodes: mammographic and ultrasonographic features. Eur J Radiol 2001; 40:24.
  40. Stavros AT, Thickman D, Rapp CL, et al. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 1995; 196:123.
  41. Flobbe K, Bosch AM, Kessels AG, et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Arch Intern Med 2003; 163:1194.
  42. Soo MS, Rosen EL, Baker JA, et al. Negative predictive value of sonography with mammography in patients with palpable breast lesions. AJR Am J Roentgenol 2001; 177:1167.
  43. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004; 233:830.
  44. Baker JA, Kornguth PJ, Soo MS, et al. Sonography of solid breast lesions: observer variability of lesion description and assessment. AJR Am J Roentgenol 1999; 172:1621.
  45. Rahbar G, Sie AC, Hansen GC, et al. Benign versus malignant solid breast masses: US differentiation. Radiology 1999; 213:889.
  46. Sickles EA, Filly RA, Callen PW. Benign breast lesions: ultrasound detection and diagnosis. Radiology 1984; 151:467.
  47. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989; 170:681.
  48. Revel D, Brasch RC, Paajanen H, et al. Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma. Radiology 1986; 158:319.
  49. Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10:199.
  50. Heywang SH, Wolf A, Pruss E, et al. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171:95.
  51. Stack JP, Redmond OM, Codd MB, et al. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990; 174:491.
  52. Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187:493.
  53. Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190:485.
  54. Pierce WB, Harms SE, Flamig DP, et al. Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress. Radiology 1991; 181:757.
  55. Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292:2735.
  56. Liberman L, Morris EA, Dershaw DD, et al. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol 2003; 180:901.
  57. DeMartini W, Lehman C. A review of current evidence-based clinical applications for breast magnetic resonance imaging. Top Magn Reson Imaging 2008; 19:143.
  58. Schelfout K, Van Goethem M, Kersschot E, et al. Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004; 30:501.
  59. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999; 213:881.
  60. Mumtaz H, Hall-Craggs MA, Davidson T, et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 1997; 169:417.
  61. Schnall MD, Blume J, Bluemke DA, et al. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol 2005; 92:32.
  62. Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999; 17:110.
  63. Esserman L, Hylton N, George T, Weidner N. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J 1999; 5:13.
  64. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001; 8:549.
  65. Gribbestad IS, Nilsen G, Fjøsne H, et al. Contrast-enhanced magnetic resonance imaging of the breast. Acta Oncol 1992; 31:833.
  66. Flickinger FW, Allison JD, Sherry RM, Wright JC. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993; 11:617.
  67. Dao TH, Rahmouni A, Campana F, et al. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 187:751.
  68. Gilles R, Guinebretière JM, Shapeero LG, et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993; 188:473.
  69. Heywang SH, Hilbertz T, Pruss E, et al. [Dynamic contrast medium studies with flash sequences in nuclear magnetic resonance tomography of the breast]. Digitale Bilddiagn 1988; 8:7.
  70. Rubens D, Totterman S, Chacko AK, et al. Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast. AJR Am J Roentgenol 1991; 157:267.
  71. Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193:777.
  72. Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995; 197:33.
  73. Peters NH, Borel Rinkes IH, Zuithoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 2008; 246:116.
  74. Tillman GF, Orel SG, Schnall MD, et al. Effect of breast magnetic resonance imaging on the clinical management of women with early-stage breast carcinoma. J Clin Oncol 2002; 20:3413.
  75. Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer 2002; 9:141.
  76. Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003; 98:468.
  77. Bilimoria KY, Cambic A, Hansen NM, Bethke KP. Evaluating the impact of preoperative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers. Arch Surg 2007; 142:441.
  78. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008; 26:3248.
  79. Bleicher RJ, Ciocca RM, Egleston BL, et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009; 209:180.
  80. Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985; 56:979.
  81. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233.
  82. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981; 305:6.
  83. Sarrazin D, Lê MG, Arriagada R, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 1989; 14:177.
  84. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000; 92:1143.
  85. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995; 332:907.
  86. Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 1992; :19.
  87. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 2010; 375:563.
  88. Turnbull LW, Brown SR, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010; 14:1.
  89. Morris EA. Should we dispense with preoperative breast MRI? Lancet 2010; 375:528.
  90. Shin HC, Han W, Moon HG, et al. Limited value and utility of breast MRI in patients undergoing breast-conserving cancer surgery. Ann Surg Oncol 2012; 19:2572.
  91. Weber JJ, Bellin LS, Milbourn DE, et al. Selective preoperative magnetic resonance imaging in women with breast cancer: no reduction in the reoperation rate. Arch Surg 2012; 147:834.
  92. Feigelson HS, James TA, Single RM, et al. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg 2013; 216:966.
  93. Kuhl CK, Strobel K, Bieling H, et al. Impact of Preoperative Breast MR Imaging and MR-guided Surgery on Diagnosis and Surgical Outcome of Women with Invasive Breast Cancer with and without DCIS Component. Radiology 2017; 284:645.
  94. https://www.acrin.org/protocolsummarytable/protocol6694.aspx (Accessed on July 08, 2017).
  95. Gonzalez V, Sandelin K, Karlsson A, et al. Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World J Surg 2014; 38:1685.
  96. Sung JS, Li J, Da Costa G, et al. Preoperative breast MRI for early-stage breast cancer: effect on surgical and long-term outcomes. AJR Am J Roentgenol 2014; 202:1376.
  97. Lai HW, Chen CJ, Lin YJ, et al. Does Breast Magnetic Resonance Imaging Combined With Conventional Imaging Modalities Decrease the Rates of Surgical Margin Involvement and Reoperation?: A Case-Control Comparative Analysis. Medicine (Baltimore) 2016; 95:e3810.
  98. Iacconi C, Galman L, Zheng J, et al. Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not? Radiology 2016; 279:378.
  99. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295.
  100. Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 2009; 27:5640.
  101. Sorbero ME, Dick AW, Beckjord EB, Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009; 16:1597.
  102. Slanetz PJ, Edmister WB, Yeh ED, et al. Occult contralateral breast carcinoma incidentally detected by breast magnetic resonance imaging. Breast J 2002; 8:145.
  103. Liberman L, Morris EA, Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol 2003; 180:333.
  104. Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003; 226:773.
  105. Pediconi F, Catalano C, Roselli A, et al. Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions. Radiology 2007; 243:670.
  106. Lehman CD, Blume JD, Thickman D, et al. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol 2005; 92:9.
  107. Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin 2009; 59:290.
  108. Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol 2012; 19:536.
  109. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.
  110. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.
  111. Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 2008; 26:703.
  112. Yeh ED, Slanetz PJ, Edmister WB, et al. Invasive lobular carcinoma: spectrum of enhancement and morphology on magnetic resonance imaging. Breast J 2003; 9:13.
  113. BRCAPRO available for downloading at www4.utsouthwestern.edu/breasthealth/cagene/ (Accessed on May 06, 2011).
  114. Shieh Y, Eklund M, Madlensky L, et al. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst 2017; 109.
  115. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.
  116. Kim DY, Moon WK, Cho N, et al. MRI of the breast for the detection and assessment of the size of ductal carcinoma in situ. Korean J Radiol 2007; 8:32.
  117. Warner E, Causer PA, Wong JW, et al. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 2011; 17:9.
  118. Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009; 27:4082.
  119. Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 1995; 196:115.
  120. Solin LJ, Orel SG, Hwang WT, et al. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008; 26:386.
  121. Morrow M. Magnetic resonance imaging in the breast cancer patient: curb your enthusiasm. J Clin Oncol 2008; 26:352.
  122. Zakhireh J, Gomez R, Esserman L. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer. Eur J Cancer 2008; 44:2742.
  123. Lehman CD, DeMartini W, Anderson BO, Edge SB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw 2009; 7:193.
  124. Morrogh M, Morris EA, Liberman L, et al. MRI identifies otherwise occult disease in select patients with Paget disease of the nipple. J Am Coll Surg 2008; 206:316.
  125. Frei KA, Bonel HM, Pelte MF, et al. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol 2005; 40:363.
  126. Hindle WH, Davis L, Wright D. Clinical value of mammography for symptomatic women 35 years of age and younger. Am J Obstet Gynecol 1999; 180:1484.
  127. Stomper PC, Winston JS, Proulx GM, et al. Mammographic detection and staging of ductal carcinoma in situ: Mammographic-pathologic correlation. Semin Breast Dis 2000; 3:1.
  128. Silverstein MJ, Recht A, Lagios MD, et al. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg 2009; 209:504.